aluates Reports

$ 0.0

Automative

Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Research Report 2024

Published Date: September 2024

Report Code: QYRE-Auto-0A18656

BUY CHAPTERS

Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Research Report 2024

Code: QYRE-Auto-0A18656

Report

September 2024

Pages:93

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

SVR Ltd.

Gilead Sciences

Asegua Therapeutics

Merck

AbbVie

Bristol–Myers Squibb

Ascletis Pharma

Kawin Technology

Yichang Hec Changjiang Pharmaceutical

Sanhome Pharmaceutical

Chia Tai-Tianqing Pharmaceutical

Cosunter Pharmaceutical

Beijing Sihuan Pharmaceutical

Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market

Antiviral drugs for the treatment of hepatitis C (HCV) are medications specifically designed to target and inhibit the hepatitis C virus, aiming to eradicate the infection and prevent liver damage.The modern treatment landscape for HCV has shifted towards direct-acting antivirals (DAAs), which are highly effective in clearing the virus. DAAs include several classes of medications such as NS3/4A protease inhibitors (e.g., simeprevir, glecaprevir), NS5A inhibitors (e.g., ledipasvir, daclatasvir), and NS5B polymerase inhibitors (e.g., sofosbuvir, dasabuvir). These drugs are typically administered in combination regimens to enhance efficacy and reduce the risk of resistance. Antiviral therapy for HCV can achieve sustained virologic response (SVR), meaning the virus is undetectable in the blood after treatment, which is considered a cure for the infection.

The global Antiviral Drugs for the Treatment of Hepatitis C (HCV) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.

Antiviral drugs for the treatment of hepatitis C (HCV) have undergone significant advancements over the past decade, marked by a shift from older therapies to highly effective direct-acting antivirals (DAAs). Early treatments, such as interferon-based therapies combined with ribavirin, were less effective and associated with considerable side effects. The development of DAAs has revolutionized HCV treatment by offering much higher cure rates, shorter treatment durations, and improved tolerability. DAAs target specific stages of the HCV lifecycle, such as viral replication and assembly, and have become the standard of care due to their high efficacy and relatively mild side effect profiles.

Recent trends in HCV antiviral therapy focus on optimizing treatment regimens and expanding access. Researchers are exploring combinations of DAAs to cover a broader range of HCV genotypes and enhance treatment success. Fixed-dose combination pills, which combine multiple DAAs in a single tablet, have simplified treatment regimens and improved patient adherence. Additionally, efforts are being made to address challenges related to drug resistance and to develop therapies that can tackle HCV strains that are less responsive to existing treatments.

Looking ahead, the development trend for antiviral drugs in HCV treatment includes ongoing research into even more effective and accessible therapies. Advances in drug formulations aim to reduce treatment durations further and minimize side effects. Moreover, there is a strong emphasis on improving global access to these life-saving treatments, particularly in low- and middle-income countries where HCV prevalence is high but access to newer therapies remains limited. Continued innovation and expanded access are expected to play crucial roles in achieving global hepatitis C eradication goals.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Antiviral Drugs for the Treatment of Hepatitis C (HCV), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antiviral Drugs for the Treatment of Hepatitis C (HCV).

The Antiviral Drugs for the Treatment of Hepatitis C (HCV) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Antiviral Drugs for the Treatment of Hepatitis C (HCV) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Antiviral Drugs for the Treatment of Hepatitis C (HCV) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Report

Report Metric	Details
Report Name	Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market
Segment by Type	NS5A Inhibitors NS5B Polymerase Inhibitors NS3/4A Protease Inhibitors Other
Segment by Application	Hospital and Clinic Pharmacy Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Gilead Sciences, Asegua Therapeutics, Merck, AbbVie, Bristol Myers Squibb, Ascletis Pharma, Kawin Technology, YiChang HEC ChangJiang Pharmaceutical, Sanhome Pharmaceutical, Chia Tai Tianqing Pharmaceutical, Cosunter pharmaceutical, Beijing Sihuan Pharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Antiviral Drugs for the Treatment of Hepatitis C (HCV) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Antiviral Drugs for the Treatment of Hepatitis C (HCV) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market report?

Ans: The main players in the Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market are Gilead Sciences, Asegua Therapeutics, Merck, AbbVie, Bristol Myers Squibb, Ascletis Pharma, Kawin Technology, YiChang HEC ChangJiang Pharmaceutical, Sanhome Pharmaceutical, Chia Tai Tianqing Pharmaceutical, Cosunter pharmaceutical, Beijing Sihuan Pharmaceutical

What are the Application segmentation covered in the Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market report?

Ans: The Applications covered in the Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market report are Hospital and Clinic, Pharmacy, Other

What are the Type segmentation covered in the Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market report?

Ans: The Types covered in the Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market report are NS5A Inhibitors, NS5B Polymerase Inhibitors, NS3/4A Protease Inhibitors, Other

Recommended Reports

Hepatitis C Therapies

Antiviral Drug Markets

Liver Disease Treatments

1 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Overview

1.1 Product Definition

1.2 Antiviral Drugs for the Treatment of Hepatitis C (HCV) by Type

1.2.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Value Comparison by Type (2024-2030)

1.2.2 NS5A Inhibitors

1.2.3 NS5B Polymerase Inhibitors

1.2.4 NS3/4A Protease Inhibitors

1.2.5 Other

1.3 Antiviral Drugs for the Treatment of Hepatitis C (HCV) by Application

1.3.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Value by Application (2024-2030)

1.3.2 Hospital and Clinic

1.3.3 Pharmacy

1.3.4 Other

1.4 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Estimates and Forecasts

1.4.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue 2019-2030

1.4.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales 2019-2030

1.4.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Competition by Manufacturers

2.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Manufacturers (2019-2024)

2.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Average Price by Manufacturers (2019-2024)

2.4 Global Key Players of Antiviral Drugs for the Treatment of Hepatitis C (HCV), Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Antiviral Drugs for the Treatment of Hepatitis C (HCV), Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Antiviral Drugs for the Treatment of Hepatitis C (HCV), Product Type & Application

2.7 Global Key Manufacturers of Antiviral Drugs for the Treatment of Hepatitis C (HCV), Date of Enter into This Industry

2.8 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Competitive Situation and Trends

2.8.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Antiviral Drugs for the Treatment of Hepatitis C (HCV) Players Market Share by Revenue

2.8.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Scenario by Region

3.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region: 2019-2030

3.2.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region: 2019-2024

3.2.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region: 2025-2030

3.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Region: 2019-2030

3.3.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Region: 2019-2024

3.3.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Region: 2025-2030

3.4 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Facts & Figures by Country

3.4.1 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2019-2030)

3.4.3 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Facts & Figures by Country

3.5.1 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2019-2030)

3.5.3 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Facts & Figures by Region

3.6.1 Asia Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Region: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region (2019-2030)

3.6.3 Asia Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Region (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Facts & Figures by Country

3.7.1 Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2019-2030)

3.7.3 Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Facts & Figures by Country

3.8.1 Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2019-2030)

3.8.3 Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2019-2030)

4.1.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2019-2024)

4.1.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2025-2030)

4.1.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Type (2019-2030)

4.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Type (2019-2030)

4.2.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Type (2019-2024)

4.2.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Type (2025-2030)

4.2.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Type (2019-2030)

4.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price by Type (2019-2030)

5 Segment by Application

5.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2019-2030)

5.1.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2019-2024)

5.1.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2025-2030)

5.1.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Application (2019-2030)

5.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Application (2019-2030)

5.2.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Application (2019-2024)

5.2.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Application (2025-2030)

5.2.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Application (2019-2030)

5.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Gilead Sciences

6.1.1 Gilead Sciences Company Information

6.1.2 Gilead Sciences Description and Business Overview

6.1.3 Gilead Sciences Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Gilead Sciences Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio

6.1.5 Gilead Sciences Recent Developments/Updates

6.2 Asegua Therapeutics

6.2.1 Asegua Therapeutics Company Information

6.2.2 Asegua Therapeutics Description and Business Overview

6.2.3 Asegua Therapeutics Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Asegua Therapeutics Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio

6.2.5 Asegua Therapeutics Recent Developments/Updates

6.3 Merck

6.3.1 Merck Company Information

6.3.2 Merck Description and Business Overview

6.3.3 Merck Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Merck Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio

6.3.5 Merck Recent Developments/Updates

6.4 AbbVie

6.4.1 AbbVie Company Information

6.4.2 AbbVie Description and Business Overview

6.4.3 AbbVie Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue and Gross Margin (2019-2024)

6.4.4 AbbVie Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio

6.4.5 AbbVie Recent Developments/Updates

6.5 Bristol Myers Squibb

6.5.1 Bristol Myers Squibb Company Information

6.5.2 Bristol Myers Squibb Description and Business Overview

6.5.3 Bristol Myers Squibb Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue and Gross Margin (2019-2024)

6.5.4 Bristol Myers Squibb Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio

6.5.5 Bristol Myers Squibb Recent Developments/Updates

6.6 Ascletis Pharma

6.6.1 Ascletis Pharma Company Information

6.6.2 Ascletis Pharma Description and Business Overview

6.6.3 Ascletis Pharma Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Ascletis Pharma Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio

6.6.5 Ascletis Pharma Recent Developments/Updates

6.7 Kawin Technology

6.7.1 Kawin Technology Company Information

6.7.2 Kawin Technology Description and Business Overview

6.7.3 Kawin Technology Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue and Gross Margin (2019-2024)

6.7.4 Kawin Technology Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio

6.7.5 Kawin Technology Recent Developments/Updates

6.8 YiChang HEC ChangJiang Pharmaceutical

6.8.1 YiChang HEC ChangJiang Pharmaceutical Company Information

6.8.2 YiChang HEC ChangJiang Pharmaceutical Description and Business Overview

6.8.3 YiChang HEC ChangJiang Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue and Gross Margin (2019-2024)

6.8.4 YiChang HEC ChangJiang Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio

6.8.5 YiChang HEC ChangJiang Pharmaceutical Recent Developments/Updates

6.9 Sanhome Pharmaceutical

6.9.1 Sanhome Pharmaceutical Company Information

6.9.2 Sanhome Pharmaceutical Description and Business Overview

6.9.3 Sanhome Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue and Gross Margin (2019-2024)

6.9.4 Sanhome Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio

6.9.5 Sanhome Pharmaceutical Recent Developments/Updates

6.10 Chia Tai Tianqing Pharmaceutical

6.10.1 Chia Tai Tianqing Pharmaceutical Company Information

6.10.2 Chia Tai Tianqing Pharmaceutical Description and Business Overview

6.10.3 Chia Tai Tianqing Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue and Gross Margin (2019-2024)

6.10.4 Chia Tai Tianqing Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio

6.10.5 Chia Tai Tianqing Pharmaceutical Recent Developments/Updates

6.11 Cosunter pharmaceutical

6.11.1 Cosunter pharmaceutical Company Information

6.11.2 Cosunter pharmaceutical Description and Business Overview

6.11.3 Cosunter pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue and Gross Margin (2019-2024)

6.11.4 Cosunter pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio

6.11.5 Cosunter pharmaceutical Recent Developments/Updates

6.12 Beijing Sihuan Pharmaceutical

6.12.1 Beijing Sihuan Pharmaceutical Company Information

6.12.2 Beijing Sihuan Pharmaceutical Description and Business Overview

6.12.3 Beijing Sihuan Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue and Gross Margin (2019-2024)

6.12.4 Beijing Sihuan Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio

6.12.5 Beijing Sihuan Pharmaceutical Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Chain Analysis

7.2 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Production Mode & Process

7.4 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales and Marketing

7.4.1 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Channels

7.4.2 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Distributors

7.5 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Customers

8 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Dynamics

8.1 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Trends

8.2 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Drivers

8.3 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Challenges

8.4 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

SVR Ltd.

Gilead Sciences

Asegua Therapeutics

Merck

AbbVie

Bristol–Myers Squibb

Ascletis Pharma

Kawin Technology

Yichang Hec Changjiang Pharmaceutical

Sanhome Pharmaceutical

Chia Tai-Tianqing Pharmaceutical

Cosunter Pharmaceutical

Beijing Sihuan Pharmaceutical

List of Tables

Table 1. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Value by Application (2024-2030) & (US$ Million)

Table 3. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Competitive Situation by Manufacturers in 2023

Table 4. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units) of Key Manufacturers (2019-2024)

Table 5. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Antiviral Drugs for the Treatment of Hepatitis C (HCV) Average Price (US$/Unit) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Antiviral Drugs for the Treatment of Hepatitis C (HCV), Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Antiviral Drugs for the Treatment of Hepatitis C (HCV), Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Antiviral Drugs for the Treatment of Hepatitis C (HCV), Product Type & Application

Table 12. Global Key Manufacturers of Antiviral Drugs for the Treatment of Hepatitis C (HCV), Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antiviral Drugs for the Treatment of Hepatitis C (HCV) as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region (2019-2024) & (K Units)

Table 18. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Region (2019-2024)

Table 19. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region (2025-2030) & (K Units)

Table 20. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Region (2025-2030)

Table 21. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Region (2019-2024)

Table 23. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Region (2025-2030)

Table 25. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2019-2024) & (K Units)

Table 27. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2025-2030) & (K Units)

Table 28. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2019-2024) & (K Units)

Table 32. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2025-2030) & (K Units)

Table 33. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region (2019-2024) & (K Units)

Table 37. Asia Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region (2025-2030) & (K Units)

Table 38. Asia Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2019-2024) & (K Units)

Table 42. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2025-2030) & (K Units)

Table 43. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Country (2019-2024)

Table 45. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2019-2024) & (K Units)

Table 47. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2025-2030) & (K Units)

Table 48. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units) by Type (2019-2024)

Table 51. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units) by Type (2025-2030)

Table 52. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Type (2019-2024)

Table 53. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Type (2025-2030)

Table 54. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Type (2019-2024)

Table 57. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Type (2025-2030)

Table 58. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price (US$/Unit) by Type (2019-2024)

Table 59. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price (US$/Unit) by Type (2025-2030)

Table 60. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units) by Application (2019-2024)

Table 61. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units) by Application (2025-2030)

Table 62. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Application (2019-2024)

Table 63. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Application (2025-2030)

Table 64. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Application (2019-2024)

Table 67. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Application (2025-2030)

Table 68. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price (US$/Unit) by Application (2019-2024)

Table 69. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price (US$/Unit) by Application (2025-2030)

Table 70. Gilead Sciences Company Information

Table 71. Gilead Sciences Description and Business Overview

Table 72. Gilead Sciences Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 73. Gilead Sciences Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product

Table 74. Gilead Sciences Recent Developments/Updates

Table 75. Asegua Therapeutics Company Information

Table 76. Asegua Therapeutics Description and Business Overview

Table 77. Asegua Therapeutics Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 78. Asegua Therapeutics Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product

Table 79. Asegua Therapeutics Recent Developments/Updates

Table 80. Merck Company Information

Table 81. Merck Description and Business Overview

Table 82. Merck Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 83. Merck Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product

Table 84. Merck Recent Developments/Updates

Table 85. AbbVie Company Information

Table 86. AbbVie Description and Business Overview

Table 87. AbbVie Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 88. AbbVie Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product

Table 89. AbbVie Recent Developments/Updates

Table 90. Bristol Myers Squibb Company Information

Table 91. Bristol Myers Squibb Description and Business Overview

Table 92. Bristol Myers Squibb Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 93. Bristol Myers Squibb Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product

Table 94. Bristol Myers Squibb Recent Developments/Updates

Table 95. Ascletis Pharma Company Information

Table 96. Ascletis Pharma Description and Business Overview

Table 97. Ascletis Pharma Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 98. Ascletis Pharma Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product

Table 99. Ascletis Pharma Recent Developments/Updates

Table 100. Kawin Technology Company Information

Table 101. Kawin Technology Description and Business Overview

Table 102. Kawin Technology Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 103. Kawin Technology Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product

Table 104. Kawin Technology Recent Developments/Updates

Table 105. YiChang HEC ChangJiang Pharmaceutical Company Information

Table 106. YiChang HEC ChangJiang Pharmaceutical Description and Business Overview

Table 107. YiChang HEC ChangJiang Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 108. YiChang HEC ChangJiang Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product

Table 109. YiChang HEC ChangJiang Pharmaceutical Recent Developments/Updates

Table 110. Sanhome Pharmaceutical Company Information

Table 111. Sanhome Pharmaceutical Description and Business Overview

Table 112. Sanhome Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 113. Sanhome Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product

Table 114. Sanhome Pharmaceutical Recent Developments/Updates

Table 115. Chia Tai Tianqing Pharmaceutical Company Information

Table 116. Chia Tai Tianqing Pharmaceutical Description and Business Overview

Table 117. Chia Tai Tianqing Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 118. Chia Tai Tianqing Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product

Table 119. Chia Tai Tianqing Pharmaceutical Recent Developments/Updates

Table 120. Cosunter pharmaceutical Company Information

Table 121. Cosunter pharmaceutical Description and Business Overview

Table 122. Cosunter pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 123. Cosunter pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product

Table 124. Cosunter pharmaceutical Recent Developments/Updates

Table 125. Beijing Sihuan Pharmaceutical Company Information

Table 126. Beijing Sihuan Pharmaceutical Description and Business Overview

Table 127. Beijing Sihuan Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 128. Beijing Sihuan Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product

Table 129. Beijing Sihuan Pharmaceutical Recent Developments/Updates

Table 130. Key Raw Materials Lists

Table 131. Raw Materials Key Suppliers Lists

Table 132. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Distributors List

Table 133. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Customers List

Table 134. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Trends

Table 135. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Drivers

Table 136. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Challenges

Table 137. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Restraints

Table 138. Research Programs/Design for This Report

Table 139. Key Data Information from Secondary Sources

Table 140. Key Data Information from Primary Sources

Table 141. Authors List of This Report

List of Figures

Figure 1. Product Picture of Antiviral Drugs for the Treatment of Hepatitis C (HCV)

Figure 2. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Share by Type: 2023 & 2030

Figure 4. NS5A Inhibitors Product Picture

Figure 5. NS5B Polymerase Inhibitors Product Picture

Figure 6. NS3/4A Protease Inhibitors Product Picture

Figure 7. Other Product Picture

Figure 8. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Value by Application (2024-2030) & (US$ Million)

Figure 9. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Share by Application: 2023 & 2030

Figure 10. Hospital and Clinic

Figure 11. Pharmacy

Figure 12. Other

Figure 13. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 14. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size (2019-2030) & (US$ Million)

Figure 15. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (2019-2030) & (K Units)

Figure 16. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Average Price (US$/Unit) & (2019-2030)

Figure 17. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Report Years Considered

Figure 18. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Share by Manufacturers in 2023

Figure 19. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Share by Manufacturers in 2023

Figure 20. Global 5 and 10 Largest Antiviral Drugs for the Treatment of Hepatitis C (HCV) Players: Market Share by Revenue in Antiviral Drugs for the Treatment of Hepatitis C (HCV) in 2023

Figure 21. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 22. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 23. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Country (2019-2030)

Figure 24. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Country (2019-2030)

Figure 25. United States Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 26. Canada Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 27. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Country (2019-2030)

Figure 28. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Country (2019-2030)

Figure 29. Germany Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. France Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. U.K. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. Italy Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. Russia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 34. Asia Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Region (2019-2030)

Figure 35. Asia Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Region (2019-2030)

Figure 36. China Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. Japan Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. South Korea Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. India Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. Australia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. China Taiwan Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. Southeast Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Country (2019-2030)

Figure 44. Mexico Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Brazil Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Argentina Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 47. Colombia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 48. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Country (2019-2030)

Figure 49. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Country (2019-2030)

Figure 50. Turkey Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 51. Saudi Arabia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 52. UAE Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 53. Global Sales Market Share of Antiviral Drugs for the Treatment of Hepatitis C (HCV) by Type (2019-2030)

Figure 54. Global Revenue Market Share of Antiviral Drugs for the Treatment of Hepatitis C (HCV) by Type (2019-2030)

Figure 55. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price (US$/Unit) by Type (2019-2030)

Figure 56. Global Sales Market Share of Antiviral Drugs for the Treatment of Hepatitis C (HCV) by Application (2019-2030)

Figure 57. Global Revenue Market Share of Antiviral Drugs for the Treatment of Hepatitis C (HCV) by Application (2019-2030)

Figure 58. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price (US$/Unit) by Application (2019-2030)

Figure 59. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Value Chain

Figure 60. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Production Process

Figure 61. Channels of Distribution (Direct Vs Distribution)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Hepatitis C Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Direct Acting Antivirals Market Research Report 2024

Global Ledipasvir Market Insights Forecast to 2030

Global Anti Hepatitis C Drugs Market Research Report 2024

Global Hepatitis C Treatment Drug Market Research Report 2024

Hepatic Antiviral Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Nesbuvir Market Research Report 2024

Global Hepatitis C Virus Drugs Market Research Report 2025

Global Hepatitis C Interferon Market Research Report 2024

Antivirals Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Chronic Hepatitis C Treatment Drugs Market Research Report 2024

Global Sofosbuvir API Market Research Report 2025

Global Influenza Flu Antiviral Drugs Market Insights Forecast to 2030

Anti Hepatitis Virus Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Antiviral Drugs for Influenza Market Research Report 2025

Hepatitis B Therapeutic Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Hepatitis B Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Ophthalmic Antivirals Market Research Report 2025

Global Velpatasvir API Market Research Report 2025

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions